# Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF

> **NCT04627025** · PHASE3 · COMPLETED · sponsor: **VectivBio AG** · enrollment: 164 (actual)

## Conditions studied

- Short Bowel Syndrome

## Interventions

- **DRUG:** apraglutide

## Key facts

- **NCT ID:** NCT04627025
- **Lead sponsor:** VectivBio AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-26
- **Primary completion:** 2024-01-02
- **Final completion:** 2024-02-22
- **Target enrollment:** 164 (ACTUAL)
- **Last updated:** 2024-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04627025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04627025, "Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT04627025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*